{"id":42436,"date":"2020-12-14T10:42:42","date_gmt":"2020-12-14T10:42:42","guid":{"rendered":"https:\/\/new.igihe.com\/covid-19-rwanda-ready-to-administer-moderna-and-astrazeneca-vaccines\/"},"modified":"2020-12-16T07:06:05","modified_gmt":"2020-12-16T07:06:05","slug":"covid-19-rwanda-ready-to-administer-moderna-and-astrazeneca-vaccines","status":"publish","type":"post","link":"https:\/\/new.igihe.com\/english\/covid-19-rwanda-ready-to-administer-moderna-and-astrazeneca-vaccines\/","title":{"rendered":"COVID-19: Rwanda ready to administer Moderna and AstraZeneca vaccines"},"content":{"rendered":"<p>Dr Ngamije made the revelation yesterday during a live talk-show on Rwanda Television.  He explained that Rwanda is among 96 countries prepared to acquire  the vaccine through World Health Organization and COVAX, a global initiative aimed at working with vaccine producers to provide countries worldwide with equitable access to safe and effective vaccine once licensed and approved.<\/p>\n<p>\u201cWe have been registered and submitted the request with detailed figures of needed vaccines.  The more vaccines are produced, the more the organization liaises with producers to identify available vaccines to be distributed to countries that expressed interest,\u201d he said.   <\/p>\n<p>\u201cWe shall cover 20% of Rwandans in the first phase through the United Nation\u2019s system.  It doesn\u2019t exclude us from engaging in discussions with other countries that might provide us with vaccines even though we have not completed the feasibility study. It is however, possible to get them from partner countries,\u201d added Ngamije.   <\/p>\n<p>He explained that Rwanda will be among first African countries receiving the vaccine once licensed and ready for distribution.  <\/p>\n<p>So  far, the country is considering three vaccines mainly; mRNA-1273 produced by Moderna Inc. from the United States of America, BNT162b2 produced by respective factories from the United States of America and Germany as well as  and  Pfizer from the United Kingdom.  <\/p>\n<p>These vaccines require storage in special temperature conditions posing need for establishing strong storage systems as they are distributed to citizens.   <\/p>\n<p>\u201cWe meet several requirements especially for two of the three requested vaccines.  We even have capacity to receive quite a number Pfizer vaccines at national level.  As for such a vaccine that should be stored at -70 Celsius, it can be designated for areas where the temperatures a very cold and store it for at least three days in ordinary refrigerators designed for vaccines,\u201d he said.  <\/p>\n<p>\u201cThis means, we are also able to use those vaccines with special storage conditions once available. As for Moderna or AstraZeneca vaccines, we can\u2019t buy refrigerators because they are available.  We are training workers and identifying targeted people in the first phase.  It is evident that we will attend to health workers at health centers and hospitals.  We also have figures of people with chronic diseases but we must prepare to spot their locations,\u201d added Ngamije.   <\/p>\n<p>He explained that they are conducting a census to establish locations of people with complicated respiratory diseases, diabetes among others to plan the distribution of vaccines accordingly once available.  <\/p>\n","protected":false},"excerpt":{"rendered":"<p>{The Minister of Health, Dr Daniel Ngamije has revealed that Rwanda has all the necessary facilities to receive, store and administer COVID-19 vaccines manufactured by Moderna and AstraZeneca pharmaceuticals that used standard ingredients while more preparations are needed for Pfizer and BioNTech administration.}<\/p>\n","protected":false},"author":62,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[72,75],"byline":[170],"hashtag":[],"class_list":["post-42436","post","type-post","status-publish","format-standard","hentry","category-news","tag-featured-news-home","tag-homenews","byline-igihe"],"bylines":[{"id":170,"name":"IGIHE","slug":"igihe","description":"","image":{"id":0,"url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&f=y&r=g","alt":"Default avatar","title":"Default avatar","caption":"","mime_type":"image\/jpeg","sizes":[]},"user_id":8}],"contributors":[{"id":170,"name":"IGIHE","slug":"igihe","description":"","image":{"id":0,"url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&f=y&r=g","alt":"Default avatar","title":"Default avatar","caption":"","mime_type":"image\/jpeg","sizes":[]},"user_id":8}],"featured_image":null,"_links":{"self":[{"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/posts\/42436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/users\/62"}],"replies":[{"embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/comments?post=42436"}],"version-history":[{"count":0,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/posts\/42436\/revisions"}],"wp:attachment":[{"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/media?parent=42436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/categories?post=42436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/tags?post=42436"},{"taxonomy":"byline","embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/byline?post=42436"},{"taxonomy":"hashtag","embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/hashtag?post=42436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}